Design, synthesis and SAR of novel 7-azaindole derivatives as potential Erk5 kinase inhibitor with anticancer activity

This publication has 33 references indexed in Scilit:

• Discovering novel 7-azaindole-based series as potent AXL kinase inhibitors
  Bioorganic & Medicinal Chemistry Letters, 2017
• ERK5 kinase activity is dispensable for cellular immune response and proliferation
  Proceedings of the National Academy of Sciences, 2016
• In silico and in vitro studies of novel 7-azaindole and 7-azaisatin derivatives as potent anticancer agents
  Medicinal Chemistry Research, 2015
• ERK5 negatively regulates tobacco smoke-induced pulmonary epithelial-mesenchymal transition
  Oncotarget, 2015
• The Azaindole Framework in the Design of Kinase Inhibitors
  Molecules, 2014
• Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones
  European Journal of Medicinal Chemistry, 2013
• Vemurafenib: the first drug approved for BRAF-mutant cancer
  Nature Reviews Drug Discovery, 2012
• Target Therapies in Lung Cancer
  BioMed Research International, 2011
• Pharmacological Inhibition of BMK1 Suppresses Tumor Growth through Promyelocytic Leukemia Protein
  Cancer Cell, 2010
• An analysis of the phosphorylation and activation of extracellular-signal-regulated protein kinase 5 (ERK5) by mitogen-activated protein kinase kinase 5 (MKK5) in vitro
  Biochemical Journal, 2003